Abstract
The prognostic factors for response to chemotherapy and the prognostic impact of response status on survival, relative to other prognostic variables, were evaluated among 53 responding (9 complete responses; 44 partial responses) and 165 non-responding patients with inoperable adenocarcinoma of the lung (ACL). Multiple logistic regression analysis, including 27 pretreatment variables, revealed that the only significant predictor of response was bidimensionally measurable disease parameter (P = 0.02), followed by brain metastases that were negatively correlated to response, although insignificantly (P = 0.10). Univariate landmark analyses among patients alive at 8, 12, 16 and 24 weeks showed a trend towards better survival for responders compared with non-responders, but did not reach a significant level at any time (P values 0.78, 0.57, 0.23 and 0.12, respectively). Death hazard ratios for responders to non-responders were 0.91, 0.89, 0.79 and 0.73. Multivariate regression analysis among patients alive at 16 weeks demonstrated a significant impact on survival for performance status, non-radical tumour resection, liver metastases and LDH, while the impact of response status in comparison was weak and insignificant. This reflects the unsatisfactory treatment results achieved in inoperable ACL, with the majority of responses being partial, and calls for improvement of the cytostatic treatment currently available.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sørensen, J., Badsberg, J. & Hansen, H. Response to cytostatic treatment in inoperable adenocarcinoma of the lung: critical implications. Br J Cancer 60, 389–393 (1989). https://doi.org/10.1038/bjc.1989.291
Issue Date:
DOI: https://doi.org/10.1038/bjc.1989.291
This article is cited by
-
Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC
Advances in Therapy (2021)
-
A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors
Journal of Neuro-Oncology (1994)
-
Is there a role for vindesine in the treatment of non-small cell lung cancer?
Investigational New Drugs (1993)